Dr. Clay Siegall is the CEO of Seattle genetics which is a biomedical research institution, and a global leader in oncology studies in the northwest Pacific. Dr. Siegall received a Ph.D. from the George Washington University. He has since achieved so much as a scientist and become a renowned force in the field of biomedical research. His career began at the Bristol-Myers Squibb pharmaceutical research institute as a senior investigative researcher. Following his brilliance and experience, he quickly climbed the ranks to a principal researcher position. His efforts started to get noticed leading to his getting taken on as a staff fellow and biotechnology fellow at the national cancer center. After achieving all these, he joined with other partners to establish the Seattle genetics LLC in 1998.
Dr. Clay Siegall has always had the best interest of patients at heart especially the cancer cases, even as he started his career in biomedical research. He has throughout the years emphasized research and innovation and the diligent implementation. It is such passion that has driven him to help companies soar when it comes to research. Dr. Siegall’s leadership has seen Seattle genetics develop the first antibody-drug conjugates, including ADCETRIS, which was approved by the FDA in 2011. He played a great role in making sure the FDA approved it, and it was available throughout the globe. This drug can now be accessed by cancer patients in over 60 countries worldwide and is a testament to his efforts in making sure the medical community prioritizes cancer treatment.
As the CEO and the chairman of the board, he achieved a milestone by managing to raise more than 1.2 billion dollars from public and private sources for Seattle Genetics. In doing so, Dr. Siegall displayed great leadership and visionary qualities. The capital raised will help advance innovative technologies in cancer treatments. His contributions, to the scientific and medical community, have seen Dr. Siegall receive accolades such as Maryland alumnus of the year in 2013.
There are no signs of slowing down for Siegel, with an arsenal of 15 patents and always reaching for new heights. He has made numerous scientific publications and keeps on sharing his depth of knowledge with the medical and science communities.